# Latiglutenase as a Treatment for Celiac Disease

> **NCT03585478** · PHASE2 · COMPLETED · sponsor: **Immunogenics, LLC** · enrollment: 79 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Latiglutenase
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03585478
- **Lead sponsor:** Immunogenics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-01-22
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2021-12-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03585478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03585478, "Latiglutenase as a Treatment for Celiac Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03585478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*